KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

AbbVie (ABBV) Accumulated Depreciation & Amortization (2016 - 2025)

AbbVie (ABBV) has disclosed Accumulated Depreciation & Amortization for 13 consecutive years, with $7.1 billion as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 7.33% to $7.1 billion in Q4 2024 year-over-year; TTM through Dec 2024 was $7.1 billion, a 7.33% increase, with the full-year FY2024 number at $7.1 billion, up 7.33% from a year prior.
  • Accumulated Depreciation & Amortization was $7.1 billion for Q4 2024 at AbbVie, up from $6.6 billion in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $7.1 billion in Q4 2024 to a low of $5.6 billion in Q4 2020.
  • A 5-year average of $6.2 billion and a median of $6.1 billion in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: increased 0.11% in 2021, then increased 9.83% in 2023.
  • AbbVie's Accumulated Depreciation & Amortization stood at $5.6 billion in 2020, then increased by 0.11% to $5.6 billion in 2021, then rose by 7.73% to $6.1 billion in 2022, then increased by 9.83% to $6.6 billion in 2023, then increased by 7.33% to $7.1 billion in 2024.
  • Per Business Quant, the three most recent readings for ABBV's Accumulated Depreciation & Amortization are $7.1 billion (Q4 2024), $6.6 billion (Q4 2023), and $6.1 billion (Q4 2022).